Literature DB >> 17387296

Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin.

Dorna Rezania1, Lubomir Sokol, Hernani D Cualing.   

Abstract

BACKGROUND: The classification of cutaneous lymphomas has been contentious. Two major competing classifications were the World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC). The principal authors met for a consensus meeting resulted in a combined classification called WHO-EORTC Classification of Cutaneous Lymphoma.
METHODS: We review the classification of "mature" or peripheral T-cell lymphoma (PTCL) with high predilection to the skin as published by the WHO-EORTC. We also highlight new information and changes from the previous classifications of cutaneous PTCL according to the WHO classification or the EORTC classification. Finally, the salient findings are compared with similar-looking nodal PTCLs with a high frequency of skin involvement.
RESULTS: This review focuses on a rare group of cutaneous PTCLs other than mycosis fungoides or its variants. Changes from the previous classifications are discussed, and the rare group of nodal PTCLs with high predilection to the skin are presented. The salient findings, diagnostic features, and treatments are included, along with summary tables and clinical-histopathologic images.
CONCLUSIONS: This review may serve as a guide for hematologists, oncologists and dermatologists in the diagnosis and management of these rare, aggressive, and often difficult to diagnose lymphomas. Although cutaneous lymphomas are morphologically identical to systemic lymphomas, the former behave differently, require divergent management, and should be recognized as separate entities. The consensus WHO-EORTC classification presents unified terminology and definitions to promote conformity in diagnosing and treating these cases, to foster a multidisciplinary approach to these often-obscure diseases, and to lead to more advances in identifying molecular targets specific to these entities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387296     DOI: 10.1177/107327480701400204

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  4 in total

1.  Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.

Authors:  Melanie G Cornejo; Michael G Kharas; Miriam B Werneck; Séverine Le Bras; Sandra A Moore; Brian Ball; Marie Beylot-Barry; Scott J Rodig; Jon C Aster; Benjamin H Lee; Harvey Cantor; Jean-Philippe Merlio; D Gary Gilliland; Thomas Mercher
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

2.  Peripheral T cell lymphoma: not otherwise specified.

Authors:  Anusha H Pai; Anne George; Deepa Adiga; Banavasi S Girisha
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

3.  Peripheral T-cell lymphoma, not otherwise specified.

Authors:  Kunal Kishor Jha; Suresh K Gupta; Harpreet Saluja; Nuwadatta Subedi
Journal:  J Family Med Prim Care       Date:  2017 Apr-Jun

4.  Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified: A Rapidly Progressive Variant of Cutaneous T-Cell Lymphoma.

Authors:  Kimberly Aderhold; Lisa Carpenter; Krysta Brown; Anthony Donato
Journal:  Case Rep Oncol Med       Date:  2015-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.